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Abstract
Background: Lifestyle change is probably the most important single action to prevent type 2 diabetes mellitus.
The purpose of this study was to assess the effects of a low-intensity individual lifestyle intervention by a physician
and compare this to the same physician intervention combined with an interdisciplinary, group-based approach in
a real-life setting.
Methods: The “Finnish Diabetes Risk score” (FINDRISC) was used by GPs to identify individuals at high risk. A
randomised, controlled design and an 18 month follow-up was used to assess the effect of individual lifestyle
counselling by a physician (individual physician group, (IG)) every six months, with emphasis on diet and exercise,
and compare this to the same individual lifestyle counselling combined with a group-based interdisciplinary
program (individual and interdisciplinary group, (IIG)) provided over 16 weeks. Primary outcomes were changes in
lifestyle indicated by weight reduction ≥ 5%, improvement in exercise capacity as assessed by VO2 max and diet
improvements according to the Smart Diet Score (SDS).
Results: 213 participants (104 in the IG and 109 in the IIG group, 50% women), with a mean age of 46 and mean
body mass index 37, were included (inclusion rate > 91%) of whom 182 returned at follow-up (drop-out rate 15%).
There were no significant differences in changes in lifestyle behaviours between the two groups. At baseline 57%
(IG) and 53% (IIG) of participants had poor aerobic capacity and after intervention 35% and 33%, respectively,
improved their aerobic capacity at least one metabolic equivalent. Unhealthy diets according to SDS were
common in both groups at baseline, 61% (IG) and 60% (IIG), but uncommon at follow-up, 17% and 10%,
respectively. At least 5% weight loss was achieved by 35% (IG) and 28% (IIG). In the combined IG and IIG group, at
least one primary outcome was achieved by 93% while all primary outcomes were achieved by 6%. Most
successful was the 78% reduction in the proportion of participants with unhealthy diet (almost 50% absolute
reduction).
Conclusion: It is possible to achieve important lifestyle changes in persons at risk for type 2 diabetes with modest
clinical efforts. Group intervention yields no additional effects. The design of the study, with high inclusion and low
dropout rates, should make the results applicable to ordinary clinical settings.
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Background
The incidence of type 2 diabetes mellitus is increasing
worldwide. Both genetic predisposition and behavioural
and environmental risk factors are needed to develop
type 2 diabetes [1]. Recent epidemiologic research sug-
gests that the increased incidence of type 2 diabetes is
largely due to changes in lifestyle factors such as diet
and physical activity [2]. Lifestyle modification in high
risk individuals has been proven effective in reducing
type 2 diabetes [3];[4], more effective than drug treat-
ment [4] and with sustained reduction in diabetes inci-
dence [5,6]. Cochrane reviews summarizes that exercise
combined with diet can decrease the incidence of type 2
diabetes in high risk individuals, but that additional
research is needed to reveal the best type of diet [7,8].
According to the International Diabetes Federation, up
to 80% of type 2 diabetes is preventable by adopting a
healthy diet and increasing physical activity. Even small
weight losses combined with about 30 minutes of activ-
ity per day, are in many instances enough to prevent or
at least postpone the disease [3,4]. One kg of weight lost
is associated with a 16% reduction in diabetes risk [9].
Meta-analysis indicate that dietary counselling inter-
ventions for persons with obesity or overweight produce
modest weight losses that diminish over time [10]. Com-
pared with diet alone, diet in combination with exercise
gives a 20% greater initial and sustained weight loss
after one year [11]. Successful weight loss studies are
usually conducted in tightly randomised, controlled
trials (RCTs) with low inclusion rates and low external
validity and applicability to clinical practice (Efficacy
studies; “Can it work?”) [12]. Effectiveness studies
("Does it work?) are usually studies with looser study
designs (often simple audits or before-after designs),
high inclusion rates, and brief feasible interventions,
with focus on the ability to maintain the intervention as
standard practice [12]. Patients included in such studies
are more often in alignment with patients met in com-
mon clinical settings. There is an unmet need to
develop practical, sustainable and low-intensity interven-
tions for the large number of people at risk for type 2
diabetes [13]. In this trial, individual lifestyle counselling
by a physician, with emphasis on diet and exercise, was
provided for individuals at risk of type 2 diabetes. The
effects of this intervention, alone or combined with an
additional group-based interdisciplinary program over
16 weeks, was assessed in a randomised, controlled
design with an 18 month follow-up.
Methods
Subjects and study design
The “Finnish Diabetes Risk score” (FINDRISC) was
used to identify individuals at high risk for type 2
diabetes, assessing waist circumference, body mass
index (BMI), age, medication against high blood pres-
sure, activity, history of high blood glucose and daily
consumption of vegetables/fruits. FINDRISC is found
to be a simple and feasible tool, i.e. fast, non-invasive,
reliable and at the start of this trial, the best available
tool for use in clinical practice (14;15). It is also a
good predictor of coronary artery disease (CAD),
stroke and total mortality [16]. The total score ranges
between 0-20. A FINDRISC-score ≥ 9 is found to
identify > 70% of new cases of drug treated type 2
diabetes within five years [14]. Hence, all general
practitioners (GPs) in the four nearest municipalities
to the hospital were each supplied with ten FIN-
DRISC-questionnaires by post, asked to use them on
patients at risk for type 2 diabetes. They were
requested to refer individuals aged 18-64 with a FIN-
DRISC-score ≥ 9 to the hospital. The Regional Com-
mittee for Medical Research Ethics of southern
Norway approved the study.
All referred individuals were assessed by the same
physician in a clinical examination. A thorough conver-
sation about family history of diabetes and heart disease
was carried out, as well as tobacco and alcohol con-
sumption assessments. Finally, the following informa-
tion, statements and advices were given:
1. the probability of type 2 diabetes can be reduced by
50% with only small changes in lifestyle and weight
2. the same changes can reduce the probability for
heart disease considerably
3. The following were emphasized:
• to increase the consumption of fruit and vegetables
• to get at least 30 minutes of activity pr. day
• to achieve at least 5% loss of weight
• to reduce the consumption of sugar and saturated
fat
• to use oil as the main source of fat
• to consume cod-liver oil daily
At the end of the consultation, participants were asked
if they wanted to participate in the study. Exclusion cri-
teria were: a diagnosis of diabetes mellitus, the presence
of serious heart, lung, kidney or liver failure, serious
psychiatric illness, substance abuse and not mastering
the Norwegian language. A written informed consent
was signed. They were randomly assigned to an “indivi-
dual physician group” (IG) or an “individual plus inter-
disciplinary group” (IIG) by use of closed envelope
method with unknown block sizes. All GPs received
written information about inclusion, group allocation
and aims and advices given. Flow of participants
through the trial is shown in Figure 1.
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Participants in the IG group consulted the study phy-
sician at six, twelve and eighteen months after randomi-
sation and otherwise received care from their GP as
usual. The study physician used elements of motiva-
tional interviewing during these consultations.
In addition, the IIG group participated in a group-
based program (≤ ten participants), one day (five
hours per day) each week for six weeks and a new
gathering after twelve weeks. A systematic review of
their situation was given, with emphasis on how to
avoid diabetes and CAD, by increasing the level of
knowledge and self-consciousness (Figure 2). The
topics for these group sessions were research findings
and factual information about nutrition and physical
activity, habit change, action plans, risk situations,
coping strategies, etc. The group intervention also
included a variety of physical training. The IIG pro-
gram was interdisciplinary (dietician, physiotherapist,
ergonomist, nurse and physician). Motivational inter-
viewing techniques were utilised. This is a well-
known, scientifically-tested method-, which outper-
forms traditional advice given in the treatment of a
broad range of behavioural problems and diseases
[17]. An individual 30-minutes consultation with a
nurse or ergonomist completed the intervention one
month after the last group meeting.
Referred 
n=234
Would not participate
n=3 
Randomised 
n=213
Allocated to individual
physician group (IG)
n=104
Lost to follow-up
n=15
•Withdrew n=1
•Never met despite reminding n=7
•Didn‘t meet last consultation n=7
Allocated to individual plus
interdisciplinary group (IIG)
n=109
Lost to follow-up
n=16
•Withdrew n=3
•Never met despite reminding n=8
•Didn‘t meet last consultation n=5
Final data
n=89
Final data 
n=93
Never met to 
consultation 
n=18
Figure 1 Flow of participants through trial.
Randomisation
Individual plus 
interdisciplinary  
group
Week 0            3          5               10            16         20             26                        52                 78
Baseline Exercisetest    6 group meetings           1 group meeting  Individual     Physician                        Physician        Physician
Exercise test Exercise test
Individual 
group
Figure 2 Overview of the study design.
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Assessments
At every visit to the study physician, the following
assessments were performed: fasting blood sample,
systolic and diastolic blood pressure (SBP and DBP)
according to recommended standards [18], waist cir-
cumference at a level midway between the lowest rib
and the iliac crest to the nearest cm, height without
shoes to the nearest cm (only first visit) and weight in
indoor clothes to the nearest 100 g. Blood pressures
were measured by an Omron M41 and weight with a
Seca 771. An oral glucose tolerance test (OGTT),
required to rule out diabetes and to identify patients
with impaired glucose tolerance (IGT), was not per-
formed prior to nor during the study. These prag-
matic inclusion criteria fits well with the aim of the
study to test the effects of step one life style interven-
tion in a group at risk for diabetes. The Smart Diet
Score questionnaire was used; a fast, simple and vali-
dated tool for food assessment resulting in a diet
score which ranges between 15 and 45 points [19]. A
diet score between 15-29 points is categorised as
“unhealthy”, 30-37 points as “somewhat unhealthy”
and ≥ 38 points as a “healthy” diet. A question was
added to the questionnaire to ascertain the number of
days with cod-liver oil consumption during the last
week.
A physical test on a treadmill was carried out during
the first month after randomisation and repeated after
six and eighteen months, to determine maximal aerobic
capacity (VO2max), utilising a modified Bruce protocol
designed for people in poor physical condition [20]. The
results were categorised into six levels according to nor-
mative data for VO2max for gender and age: very poor,
poor, fair, good, excellent and superior aerobic capacity
[21]. An increase in exercise capacity of 3,5 ml/kg per
minute (one metabolic equivalent (MET)) is shown to
be associated with a 12 percent improvement in survival
[22].
Definition of end points
Primary outcomes were changes in lifestyle according to
established goals that have been shown to reduce inci-
dence of type 2 diabetes, improve health and to improve
cardiovascular risk profile. These were defined as:
• weight reduction ≥ 5% [23]
• reduction in waist circumference of ≥ 5 cm [24]
• improvement in exercise capacity of one MET [22]
• consumption of cod-liver oil ≥ five days per week
[25]
• ≥ 4 point increase in Smart Diet Score. The out-
come for this diet change is an arbitrary threshold
which is not evidence based. It reflects an improve-
ment in four out of 15 areas of diet
Statistical analyses
Sample size was based upon a decision that a difference
between groups in all main outcomes of > 20% was
clinically important. Therefore, number needed to treat
(NNT) = five, to experience one extra person with a
favourable main outcome with the additional group ses-
sion approach. The spontaneous rate of achieving the
primary outcomes was estimated to be approximately
20%. The dropout rate was estimated to 15-20%. On the
basis of these assumptions, with a power > 80% (b ≤
0.20), a significance level a ≤ 0.05, and a two-sided test,
the appropriate study size was calculated to be 200 par-
ticipants, with 100 in each group. Statistical package for
Social Sciences 16 (SPSS Inc. Chicago, USA) was
employed for statistical analyses. The c2 test was used
to assess the differences between groups when variables
were categorical and McNemar test when testing
within-group changes from baseline to follow-up. The
independent sample t-test was used to assess differences
in means between study groups for continuous variables
with normal distribution. Paired t-test was used for
(within-group) comparisons of quantitative data between
baseline and follow-up at 18 months.
Results
65 GPs out of about 90 referred 234 individuals from
March 2004 to September 2005. 216 turned up for con-
sultation (Figure 1). 213 participants were randomised
(inclusion rate > 91%) of whom 182 completed the
study (> 85%). Mean (standard deviation = SD) FIN-
DRISC score was 12,0 (2,7) for the IG-group and 12,3
(2,8) for the IIG-group. 173 answered the diet question-
naire at the end of study (95% of completers). 201 per-
formed the treadmill test at baseline (94% of included),
168 after six months and 131 (72% of completers) at the
end of the study. The dropout rate from baseline to end
of study was comparable in the IG- and the IIG group
(15%), and comparable between genders. The drop-outs,
as compared with completers, were 3,8 years younger
(43,2 versus 47,0), more often on antidepressants (23%
versus 6%), had higher BMI (38,9 versus 36,4), lower
aerobic capacity (24,1 versus 27,2), lower diet score
(27,5 versus 29,0) and doubled frequency of both daily
smoking (50% versus 21%) and long term sick leave or
disability (57% versus 28%), (all p values < 0.05). Partici-
pants in the IIG group attended on average five (5,2) of
the seven group meetings, and 94% attended the final,
individual consultation and assessment.
Randomisation seemed successful for all baseline vari-
ables except for BMI. Participants in the IG group had sig-
nificantly lower BMI than persons in the IIG group (Table
1). 90% of participants were obese (BMI > 30). Weight
reducing drugs (orlistat or sibutramin) were used by 10%
in the IG-group and 5% in the IIG-group at baseline (p =
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0,15), at follow-up they were used by 4% in the IG-group
and by 5% in the IIG-group (p = 0,79). None were using
metformin or glitazones. Anti-hypertensive drugs were
used among 36% of all at baseline and 37% at follow-up.
The percentage of subjects with hypertension (defined by
systolic blood pressure ≥ 140 mmHg and/or diastolic pres-
sure ≥ 90 mmHg [26] or use of anti-hypertensive drugs)
was 71% in the IG-group and 76% in the IIG-group (p =
0,25) at baseline, and 79% and 82% (p = 0,40), respectively,
at follow-up. Hypertension were seen more often among
subjects using anti-hypertensive drugs compared to sub-
ject not using it at baseline, i.e. 75% versus 59%, respec-
tively (p = 0,02), but at follow-up this difference was not
significant, 76% versus 65% respectively (p = 0,13).
Poor or very poor aerobic capacity was found in
55% of all participants, and was twice as frequent
among men (75%) as among women (36%), (p <
0,001). Aerobic capacity at baseline was weakly, inver-
sely correlated with BMI (r2 = 0,22, p < 0,001). An
unhealthy diet was found in 60% of all participants,
and more frequently among daily smokers (76%) com-
pared with the occasional- and non-smokers (55%), (p
= 0,008). More than two-thirds had lower education
(primary or secondary education only). For individuals
with primary and/or secondary education only, mean
diet score was 2,2 points lower (p < 0,001), mean
aerobic capacity 4,6 ml/kg/min. lower (p < 0,001) and
the frequency of daily smoking more than doubled
(30% versus 12%, p = 0,006), compared to those with
higher education.
From baseline to follow-up there were no significant,
additional effects of group intervention (Tables 1 and 2).
Thus, the forthcoming results are presented as before-
after differences for all participants combined. At least
one primary outcome (Table 2) was achieved by 93%
while all primary outcomes were achieved by 6%, indi-
cating an important change in lifestyle. Most successful
was the 78% reduction in the proportion of participants
with unhealthy diet (almost 50% absolute reduction, Fig-
ure 3). The number of individuals consuming cod-liver
oil ≥ 5 days per week increased by 25% and was thereby
doubled. There was a mean increase in maximal aerobic
capacity of 9% which was evident after six months and
thereafter stable. One third of participants improved
their aerobic capacity to an extent which is known to
improve health (1 MET). Mean weight loss from base-
line was modest: 1,9 kg (SD 5,6), 2,0 kg (SD 6,2) and 2,8
kg (SD 7,1) respectively, at 6, 12 and 18 months assess-
ments, with no gender differences. One-third had a
weight reduction ≥ 5% (mean 9,4% (SD 4,0)), one third
had a weight reduction less than 5% (mean 2,1% (SD
1,4)) and the last third gained weight (mean 4,0% (SD
3,8)). From baseline to follow-up there were no change
in the proportion of participants with plasma glucose ≥
7,0 mmol/l (6%), IFG (15%) or normoglycemia (79%),
and no between group differences.
Discussion
This study confirms that changes in lifestyle are possible
in individuals at risk for type 2 diabetes, with modest
clinical effort. This applies to both genders regardless of
educational status. Almost half of participants aban-
doned their unhealthy diet, one third obtained a health-
improving weight loss and one third improved their fit-
ness by one MET. Adding interdisciplinary group-based
counselling to the individual physician-based interven-
tion, gave no additional effects.
Limitations of the study must be considered. First,
dietary intake was assessed by self-report and may pre-
sent a source of recall bias. General underreporting
compounded with food-specific underreporting is fre-
quent and may increase with increasing BMI [27,28].
Second, 28% of completers failed to perform the tread-
mill test, which weakens the results for change in fit-
ness. We can consider the worst case scenario i.e. that
all who did not attend the last test and all who dropped
out did not improve their aerobic capacity. The success
rate would then fall from 33 to 20% if success is defined
as improvement of VO2max of 1 MET. However, we
contend that compliance with treadmill testing for
almost three fourths of completers in such an unse-
lected study population is a high standard result. Third,
the study-physician (first author) was not blinded to the
randomisation status of the participants. This may have
biased the results. Fourth, dropouts differed from parti-
cipants who completed testing by being younger and
having poorer lifestyle parameters. Hence, withdrawal in
this study does not occur at random, but is more com-
mon among individuals who are dissatisfied with their
life style [10]. It is a paradox, and a major healthcare
challenge, that those who have greatest need for a
change in lifestyle are also those who are most likely to
discontinue an intervention. Fifth, the generalisability of
the findings in this study could be limited by self-selec-
tion bias or healthy volunteer bias. Thus, extrapolating
these results to the general population may overestimate
the effects. However, the results should be valid for
patients at risk for diabetes according to the FINDRISC
questionnaire.
A major strength of this study is the low drop-out rate
compared with other weight loss studies. A meta analy-
sis of 121 pharmaceutical randomised controlled trials
with weight loss or weight gain prevention as major end
points, found a drop-out rate of 37% at one year [29].
Studies including behaviour modification among over-
weight and obese out-patients report drop-out rates
after one and two years of 53-77% [30,31]. The aim of
this study was to evaluate a practical and low-intensity
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Table 2 Success in achieving primary outcomes by 18 months according to treatment group by proportions (%).
Primary outcome Individual physician
group (IG)
n = 89
Individual and interdiciplinary group (IIG)
n = 93
P value* All
n = 182
1. Weight reduction ≥ 5% 36 28 0,25 32
2. Waist circumference reduction ≥ 5 cm 42 30 0,11 36
3. Improved diet score ≥ 4 points 55 63 0,28 59
4. Cod-liver oil at least 5 days a week 43 54 0,15 49
Exercise test from baseline to follow-up n = 63 n = 64
1. Improved exercise test ≥ 1MET 35 33 0,80 34
* The c2 test
Table 1 Baseline characteristics of 213 included subjects and changes in selected clinical and metabolic variables from
baseline to follow-up at 18 months among 182 completers of the study.
Individual physician group
(IG)
n = 104
Individual plus interdisciplinary
group (IIG)
n = 109
All
n = 213
Baseline Baseline Baseline
Age 45,9 (11) 47,0 (11) 46,5 (11)
Gender, men, % 53 47 50
Married or cohabiting, % 79 69 74
High school or university, % 27 29 28
Employed, % 64 61 62
BMI 35,9 (6) 37,6 (6) 36,8 (6)
Baseline Follow-up P value Baseline Follow-up P value Baseline Follow-up Δ-value P value
n = 89 n = 93 n = 182
Weight, kg 111,7 (22) 108,7 (23) < 0,001* 110,5 (22) 108,0 (20) 0,001* 111,1(22) 108,3 (21) 2,8 < 0,001*
BMI, kg/m2 35,8 (6) 34,8 (6) < 0,001* 37,0 (6) 36,2 (6) < 0,001* 36,4 (6) 35,5 (6) 0,9 < 0,001*
Waist circumference, cm 119 (14) 115 (15) < 0,001* 118 (15) 116 (14) < 0,001* 118 (14) 115 (14) 3 < 0,001*
Aerobic capacity, ml/kg/min2 2 27,4 (8) 29,8 (8) < 0,001* 26,4 (8) 28,7 (7) < 0,001* 26,9 (8) 29,2 (7) 2,3 < 0,001*
Heart rate at end of exercise test 2 159 (22) 163 (21) 0,009* 159 (19) 161 (21) 0,17* 159 (20) 162 (21) 3 0,004*
SBP, mmHg 144 (18) 147 (19) 0,09* 144 (20 143 (19) 0,84* 144 (19) 145 (19) 1 0,37*
DBP, mmHg 90 (11) 91 (10) 0,42* 88 (10) 91 (11) 0,03* 89 (11) 91 (11) 2 0,04*
Fasting plasma glucose, mmol/l 5,5(0,8) 5,6(0,7) 0,69* 5,6(0,8) 5,8(1,2) 0,06* 5,6(0,8) 5,7(1,0) 0,1 0,08*
HbA1c, % 5,6 (0,4) 5,6 (0,5) 0,11* 5,6 (0,4) 5,6 (0,5) 0,91* 5,6 (0,4) 5,6 (0,5) 0 0,29*
Total cholesterol, mmol/l 5,5 (1,1) 5,3 (1,0) 0,09* 5,4 (1,1) 5,2 (1,1) 0,07* 5,4 (1,1) 5,3 (1,0) 0,1 0,01*
HDL cholesterol, mmol/l 1,18 (0,3) 1,23 (0,3) 0,006* 1,28 (0,4) 1,25 (0,4) 0.17* 1,23 (0,4) 1,24 (0,3) 0,01 0,40*
Triglycerides, mmol/l 1,9 (1,0) 1,6 (0,7) < 0,001* 1,8 (1,4) 1,5 (0,8) 0,01* 1,9 (1,2) 1,5 (0,7) 0,4 < 0,001*
Diet score, mean 29 (4) 33 (4) < 0,001* 29 (4) 34 (3) < 0,001* 29 (4) 34 (4) 5 < 0,001*
Healthy diet, % of all 2 16 0,007# 1 20 < 0,001# 2 18 16 < 0,001#
Unhealthy diet, % of all 60 17 < 0,001# 56 10 < 0,001# 58 13 45 < 0,001#
Daily smoking, % 21 17 0,22# 18 18 1,0# 20 17 3 0,34#
Days/week using cod liver oil 1,8 (3) 3,4 (3) < 0,001* 1,8 (3) 4,1 (3) < 0,001* 1,8 (3) 3,7 (3) 1,9 < 0,001*
Cod liver oil ≥ 5 days per week 25 43 0,02# 26 54 < 0,001# 25 49 24 < 0,001#
Values are means with standard deviations in parenthesis, unless stated otherwise.
1Inter-group differences with p < 0.05 based on Chi-Square test for categorical variables and independent sample t-test for quantitative data
*paired sample t test # McNemar test
2 N = 63 & n = 66 in the IG and IIG group, respectively
Δ-value displays the actual difference between baseline and follow-up
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intervention with high external validity. An inclusion
rate of > 91% of those referred and a participation rate
of > 98% among those who turned up for consultation,
no excluded individuals and a drop-out rate < 15%, is in
accordance with this aim and increases the general
applicability of the study results to common clinical set-
tings. Low education was associated with a poorer diet,
lower aerobic capacity and smoking, as found in other
studies and reviews [32,33]. These factors and their
interactions are possible confounders. These associations
were not tested in an interaction term, since such
results cannot be utilized in any clinically meaningful
way. However, education level did not affect the success
with respect to primary outcome achievements.
An unexpected finding was the much higher preva-
lence of poor or very poor aerobic capacity for gender
and age at baseline among males compared with
females. Some of the difference can be explained by a
lower heart rate among males at the end of the first
exercise test. This finding may reflect lower motivation
and maximal effort, but may also be influenced by a
trend toward more common use of beta blockers among
men than women (25% versus 15%, p = 0,08). However,
at the final test, both use of beta blockers and maximal
heart rate was comparative between genders (20% versus
19%, p = 0,84). Further, the lower aerobic capacity
observed in males was not explained by higher BMI.
Indeed, BMI in males tended to be lower than in the
female group (36,1 versus 37,4, p = 0,10). Therefore
given that neither beta blocker use nor BMI differences
explain the lower aerobic capacity observed in this
group of obese males, we do not have a clear explana-
tion for the difference observed between genders. We
note that FINDRISC has a better ability to detect men
than women with low aerobic capacity. As far as we
know, no one before has previously described the aero-
bic capacity in individuals screened by FINDRISC.
The short duration and low intensity intervention may
explain the absence of additive effect for the group-
based, interdisciplinary approach. Svetkey et al found a
8,5 kg initial weight loss in 1032 overweight or obese
adults with hypertension/dyslipidemia after six months
with 20 group-based meetings, but gradually this weight
loss was reduced over the next 30 months to 3,5 kg [34].
Although statistically significant, there was little differ-
ence in final weight loss with regard to whether they
after the first six months were randomised to monthly
personal contact, free use of internet technology or self-
directed control. Modest weight loss is nonetheless clini-
cally important since there is a preferential loss of the
more pathogenic visceral adipose tissue (VAT) compared
with subcutaneous abdominal adipose tissue (SAT) with
modest weight loss [35]. A Cochrane review of long-term
non-pharmacological weight loss interventions for adults
with pre-diabetes, found weight loss of 2,8 kg and 2,6 kg,
respectively, after one and two years, which is compar-
able with the weight loss in this study [36]. Further, the
weight loss in this study is even more clinically important
if this result is compared with the natural concomitant
weight gain found in population-based surveys [37,38].
61
17
60
10
0
10
20
30
40
50
60
70
Baseline Follow-up
IG IIG
n = 104             109
p= 0.21
p<0,001
p<0,001
n = 84             89
%
Figure 3 Reduction in proportion of patients with unhealthy diet from baseline to follow-up.
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The effects on glucose metabolism and lipids were
modest. Despite the favourable lifestyle changes
achieved, no difference was observed in the fasting
plasma glucose and HbA1c values, or the proportion of
subjects with impaired fasting glucose, within the 18-
month study duration. Subgroup analyses including par-
ticipants with both ≥ 5% weight reduction and improved
aerobic capacity ≥ 1 MET (n = 24) showed statistically
significant (p < 0.05) changes from baseline to follow-
up; a HbA1c reduction from 5,8 to 5,5%, drop in trigly-
ceride levels from 2,0 to 1,3 mmol/l and in total choles-
terol from 5,5 to 5,0 mmol/l. Blood pressure was not
improved, in fact there was an increase in diastolic
blood pressure in the IIG group. The prevalence of
hypertension was very high, and higher among users of
antihypertensive medications. Subgroup analyses includ-
ing the same 24 participants from above with both ≥ 5%
weight reduction and improved aerobic capacity ≥ 1
MET, showed systolic/diastolic blood pressure reduction
of 7/4 mmHg which significantly differed compared to a
rise of 3/3 mmHg in the rest of the participants. Favour-
able metabolic improvements were achieved among sub-
jects who significantly changed their lifestyle, not among
the others. Use of anti-hypertensive or lipid lowering
drugs did not change during the study.
Is there a lack of knowledge with regard to what per-
sons at risk of type 2 diabetes should do to avoid type-2
diabetes? The “Study to Help Improve Early evaluation
and management of risk factors Leading to Diabetes”
(SHIELD) demonstrates appropriate knowledge and
healthy attitudes in individuals with or at risk for type 2
diabetes [39]. Despite this, only 28% of individuals at
high risk for diabetes were exercising regularly and only
14% were following a prescribed diet. Patient empower-
ment has been advocated as an approach to improve
this gap between patient knowledge and behaviour [39],
which is comparable to the principles of Motivational
Interviewing (MI) used in our study. Although different
“dosages” of MI were performed in the IG and IIG
groups, both groups were approached with MI, which
may partly explain the lack of differences between inter-
vention groups.
Previously published clinical trials show impressive
results with relative risk reductions for type 2 diabetes
of 58% for individuals with impaired glucose tolerance
(IGT) [3,4]. Despite this, the World Health Organization
estimates that the number of diabetes deaths will double
between 2005 and 2030. In many European countries
and in the US, adult obesity has reached epidemic pro-
portions with a prevalence of approximately 34%
[38,40], coupled with a 34% prevalence of overweight
[38]. Strategies to prevent weight gain on a population
level are poorly understood [41] and there remains a
lack of evidence for an effective intervention to prevent
obesity [42]. To stop the epidemic, collaboration
between academic, governmental, industrial and health
care sectors is needed [43]. This implies that elements
such as food supply, the availability of sweets, transport
policy, advertising, labelling and prices have to be evalu-
ated. Until governmental implementation of effective
strategies to reduce the invasion of the metabolic syn-
drome is assured, an individual approach as shown in
this study can be utilised with modest clinical efforts
and clinically important results.
Conclusion
FINDRISC identifies subjects with high frequency of
unhealthy lifestyle parameters. It is possible to accom-
plish important lifestyle changes in these subjects with
modest efforts to prevent or delay development of type
2 diabetes or cardiovascular disease. Group intervention
yields no additional effects. The results should be applic-
able to ordinary clinical settings.
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